1.
An. bras. dermatol
; An. bras. dermatol;95(2): 221-237, Mar.-Apr. 2020. tab, graf
Artigo
em Inglês
| LILACS, ColecionaSUS
| ID: biblio-1130848
RESUMO
Abstract With the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences.